Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients

I. Ying Kuo, Jia Ming Chang, Shih Sheng Jiang, Chung Hsin Chen, I. Shou Chang, Bor Shyang Sheu, Pei Jung Lu, Wei Lun Chang, Wu Wei Lai, Yi Ching Wang

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Esophageal squamous cell carcinoma (ESCC) is an aggressive cancer with poor prognosis. We aimed to identify a panel of CpG methylation biomarkers for prognosis prediction of ESCC patients. Methods: Illumina's GoldenGate methylation array, supervised principal components, Kaplan-Meier survival analyses and Cox regression model were conducted on dissected tumor tissues from a training cohort of 40 ESCC patients to identify potential CpG methylation biomarkers. Pyrosequencing quantitative methylation assay were performed to validate prognostic CpG methylation biomarkers in 61 ESCC patients. The correlation between DNA methylation and RNA expression of a validated marker, SOX17, was examined in a validation cohort of 61 ESCC patients. Results: We identified a panel of nine CpG methylation probes located at promoter or exon1 region of eight genes including DDIT3, FES, FLT3, NTRK3, SEPT5, SEPT9, SOX1, and SOX17, for prognosis prediction in ESCC patients. Risk score calculated using the eight-gene panel statistically predicted poor outcome for patients with high risk score. These eight-gene also showed a significantly higher methylation level in tumor tissues than their corresponding normal samples in all patients analyzed. In addition, we also detected an inverse correlation between CpG hypermethylation and the mRNA expression level of SOX17 gene in ESCC patients, indicating that DNA hypermethylation was responsible for decreased expression of SOX17. Conclusions: This study established a proof-of-concept CpG methylation biomarker panel for ESCC prognosis that can be further validated by multiple cohort studies. Functional characterization of the eight prognostic methylation genes in our biomarker panel could help to dissect the mechanism of ESCC tumorigenesis.

Original languageEnglish
Pages (from-to)779-787
Number of pages9
JournalInternational Journal of Medical Sciences
Volume11
Issue number8
DOIs
Publication statusPublished - 2014 May 30

Fingerprint

Methylation
Biomarkers
Genes
Esophageal Squamous Cell Carcinoma
Neoplasms
Kaplan-Meier Estimate
DNA Methylation
Survival Analysis
Proportional Hazards Models
Carcinogenesis
Cohort Studies
RNA
Messenger RNA
DNA

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{36df8f7d9450401687280c73b5a6cd0b,
title = "Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients",
abstract = "Background: Esophageal squamous cell carcinoma (ESCC) is an aggressive cancer with poor prognosis. We aimed to identify a panel of CpG methylation biomarkers for prognosis prediction of ESCC patients. Methods: Illumina's GoldenGate methylation array, supervised principal components, Kaplan-Meier survival analyses and Cox regression model were conducted on dissected tumor tissues from a training cohort of 40 ESCC patients to identify potential CpG methylation biomarkers. Pyrosequencing quantitative methylation assay were performed to validate prognostic CpG methylation biomarkers in 61 ESCC patients. The correlation between DNA methylation and RNA expression of a validated marker, SOX17, was examined in a validation cohort of 61 ESCC patients. Results: We identified a panel of nine CpG methylation probes located at promoter or exon1 region of eight genes including DDIT3, FES, FLT3, NTRK3, SEPT5, SEPT9, SOX1, and SOX17, for prognosis prediction in ESCC patients. Risk score calculated using the eight-gene panel statistically predicted poor outcome for patients with high risk score. These eight-gene also showed a significantly higher methylation level in tumor tissues than their corresponding normal samples in all patients analyzed. In addition, we also detected an inverse correlation between CpG hypermethylation and the mRNA expression level of SOX17 gene in ESCC patients, indicating that DNA hypermethylation was responsible for decreased expression of SOX17. Conclusions: This study established a proof-of-concept CpG methylation biomarker panel for ESCC prognosis that can be further validated by multiple cohort studies. Functional characterization of the eight prognostic methylation genes in our biomarker panel could help to dissect the mechanism of ESCC tumorigenesis.",
author = "Kuo, {I. Ying} and Chang, {Jia Ming} and Jiang, {Shih Sheng} and Chen, {Chung Hsin} and Chang, {I. Shou} and Sheu, {Bor Shyang} and Lu, {Pei Jung} and Chang, {Wei Lun} and Lai, {Wu Wei} and Wang, {Yi Ching}",
year = "2014",
month = "5",
day = "30",
doi = "10.7150/ijms.7405",
language = "English",
volume = "11",
pages = "779--787",
journal = "International Journal of Medical Sciences",
issn = "1449-1907",
publisher = "Ivyspring International Publisher",
number = "8",

}

Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients. / Kuo, I. Ying; Chang, Jia Ming; Jiang, Shih Sheng; Chen, Chung Hsin; Chang, I. Shou; Sheu, Bor Shyang; Lu, Pei Jung; Chang, Wei Lun; Lai, Wu Wei; Wang, Yi Ching.

In: International Journal of Medical Sciences, Vol. 11, No. 8, 30.05.2014, p. 779-787.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients

AU - Kuo, I. Ying

AU - Chang, Jia Ming

AU - Jiang, Shih Sheng

AU - Chen, Chung Hsin

AU - Chang, I. Shou

AU - Sheu, Bor Shyang

AU - Lu, Pei Jung

AU - Chang, Wei Lun

AU - Lai, Wu Wei

AU - Wang, Yi Ching

PY - 2014/5/30

Y1 - 2014/5/30

N2 - Background: Esophageal squamous cell carcinoma (ESCC) is an aggressive cancer with poor prognosis. We aimed to identify a panel of CpG methylation biomarkers for prognosis prediction of ESCC patients. Methods: Illumina's GoldenGate methylation array, supervised principal components, Kaplan-Meier survival analyses and Cox regression model were conducted on dissected tumor tissues from a training cohort of 40 ESCC patients to identify potential CpG methylation biomarkers. Pyrosequencing quantitative methylation assay were performed to validate prognostic CpG methylation biomarkers in 61 ESCC patients. The correlation between DNA methylation and RNA expression of a validated marker, SOX17, was examined in a validation cohort of 61 ESCC patients. Results: We identified a panel of nine CpG methylation probes located at promoter or exon1 region of eight genes including DDIT3, FES, FLT3, NTRK3, SEPT5, SEPT9, SOX1, and SOX17, for prognosis prediction in ESCC patients. Risk score calculated using the eight-gene panel statistically predicted poor outcome for patients with high risk score. These eight-gene also showed a significantly higher methylation level in tumor tissues than their corresponding normal samples in all patients analyzed. In addition, we also detected an inverse correlation between CpG hypermethylation and the mRNA expression level of SOX17 gene in ESCC patients, indicating that DNA hypermethylation was responsible for decreased expression of SOX17. Conclusions: This study established a proof-of-concept CpG methylation biomarker panel for ESCC prognosis that can be further validated by multiple cohort studies. Functional characterization of the eight prognostic methylation genes in our biomarker panel could help to dissect the mechanism of ESCC tumorigenesis.

AB - Background: Esophageal squamous cell carcinoma (ESCC) is an aggressive cancer with poor prognosis. We aimed to identify a panel of CpG methylation biomarkers for prognosis prediction of ESCC patients. Methods: Illumina's GoldenGate methylation array, supervised principal components, Kaplan-Meier survival analyses and Cox regression model were conducted on dissected tumor tissues from a training cohort of 40 ESCC patients to identify potential CpG methylation biomarkers. Pyrosequencing quantitative methylation assay were performed to validate prognostic CpG methylation biomarkers in 61 ESCC patients. The correlation between DNA methylation and RNA expression of a validated marker, SOX17, was examined in a validation cohort of 61 ESCC patients. Results: We identified a panel of nine CpG methylation probes located at promoter or exon1 region of eight genes including DDIT3, FES, FLT3, NTRK3, SEPT5, SEPT9, SOX1, and SOX17, for prognosis prediction in ESCC patients. Risk score calculated using the eight-gene panel statistically predicted poor outcome for patients with high risk score. These eight-gene also showed a significantly higher methylation level in tumor tissues than their corresponding normal samples in all patients analyzed. In addition, we also detected an inverse correlation between CpG hypermethylation and the mRNA expression level of SOX17 gene in ESCC patients, indicating that DNA hypermethylation was responsible for decreased expression of SOX17. Conclusions: This study established a proof-of-concept CpG methylation biomarker panel for ESCC prognosis that can be further validated by multiple cohort studies. Functional characterization of the eight prognostic methylation genes in our biomarker panel could help to dissect the mechanism of ESCC tumorigenesis.

UR - http://www.scopus.com/inward/record.url?scp=84901848280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901848280&partnerID=8YFLogxK

U2 - 10.7150/ijms.7405

DO - 10.7150/ijms.7405

M3 - Article

C2 - 24936140

AN - SCOPUS:84901848280

VL - 11

SP - 779

EP - 787

JO - International Journal of Medical Sciences

JF - International Journal of Medical Sciences

SN - 1449-1907

IS - 8

ER -